Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - MAb Therapeutics
 More »

  • Ovarian Cancer Treatment Options Multiply
    ... In vitro studies show it inhibits natural killer cells and modulates regulatory T cells. Therefore, mAb therapeutics look promising in blocking immune inhibition. CGEN-15049 is ...
    10-8-2013
  • Literature Review: Probing Protein Oligomerization
    ... AGR2 bound to either peptide or Reptin was detected using MAB3.4 and quantified using ... small molecules that regulate its biochemical activity as potential cancer therapeutics. ...
    9-25-2013
  • Bayer Collaboration Could Net $540M+ for Compugen
    candidates and four monoclonal antibody (mAb) drug candidates against ... Bayer holds rights to resulting cancer therapeutics Bayer Collaboration Could Net $540M+ ...
    8-5-2013
  • Consortium Wins $8M for Athera CV Drug PC-mAB
    therapeutics. EU grant will fund three-fourths of nearly €8M ($10.67M) budget toward development costs up until proof-of-concept. Consortium Wins $8M for Athera CV Drug PC-mAB
    6-17-2013
  • RuiYi Licenses mAb Development to China's Genor
    with them to deliver novel, breakthrough therapeutics for the Chinese healthcare system." ... especially rheumatoid arthritis. RuiYi Licenses mAb Development to China's Genor
    5-16-2013
  • Heightened Characterization of Therapeutic mAbs Using a Novel...
    Quality control and analysis of monoclonal antibody (mAb) therapeutics is required throughout therapeutic development and production. In particular, deep characterization of ...
    5-15-2013
  • RuiYi, CMC Collaborate to Speed mAb Development
    of protein-based therapeutics for preclinical, clinical trials, and in-market production. ... designed to fight inflammation and cancer RuiYi, CMC Collaborate to Speed mAb Development
    5-14-2013
  • Literature Review: Which Drug Combination Will Unlock Triple...
    form of breast cancer that does not currently have any targeted therapeutics available. ... They were able to find two EGFR antibodies (panitumumab and mAb111) that are ...
    4-25-2013
  • Small Firms Look Optimistically to Future
    ... Bertilimumab, a fully human mAb targeting eotaxin-1, has a direct correlation with ... Elcelyx Therapeutics is using its gut sensory modulators (GSMs) to target diabetes and ...
    3-1-2013
  • Shire Rare-Disease Partnerships Expand
    ... tumors, is on track for filing this year. Shire launchs alliance with ethris, expands year-long mAB therapeutics collaboration with arGEN-X. Shire Rare-Disease Partnerships Expand
    1-7-2013
  • Where Downstream Operations Are Headed
    New technologies are being used in the initial stage of the downstream process to help overcome process bottlenecks and drive down cost-of-goods (COG) of mAb therapeutics. Aloke ...
    1-1-2013
  • Cancer Research Firms Eye ADCs to Extend Portfolios
    ... agent, a biodegradable linker, and a mAb, diabody, or ScV (single chain variable) ... II trials in 2010 for ovarian cancer, and agreements with Genentech and ADC Therapeutics. ...
    12-1-2012
  • TG Enters mAb Therapeutic Agreement for South Korea, SE Asia
    TG Therapeutics entered into an exclusive licensing agreement with Ildong Pharmaceutical ... South Korea and Southeast Asia. TG Enters mAb Therapeutic Agreement for South Korea, SE ...
    11-15-2012
  • Firms Ally to Develop Humira Biosimilar
    AET BioTech and BioXpress Therapeutics are pooling their expertise to develop a biosimilar ... is a Swiss biotech focused on the development of monoclonal antibody (mAb) biosimilars. ...
    10-30-2012
  • RuiYi Nabs Rights to arGEN-X IL-6 mAb
    The merged entity's expertise combines Anaphore's Atrimer protein therapeutics platform, ... preclinical anti-IL-6 monoclonal antibody ARGX-109. RuiYi Nabs Rights to arGEN-X IL-6 mAb
    10-4-2012

  • Journal Articles

  • Monoclonal Antibody-Based Candidate Therapeutics Against HIV...
    Weizao Chen, Dimiter S. Dimitrov
    AIDS Research and Human Retroviruses
    in vitro and in vivo antiviral efficacy, mechanisms used by HIV-1 to escape them, and strategies that could be effective to develop more powerful mAb-based HIV-1 therapeutics.
  • Production and Characterization of Monoclonal Antibody Specific...
    Qun-Xing An, Xin Lv, Xing-Bin Hu, Zhi-Kai Xu, Jing Yang, Ying-Feng Lei, Wen Yin, San-Hua Wei
    Hybridoma
    Likewise, one MAb could inhibit the NS3 helicase enzymatic activity distinctly in the NS3 ... diagnostic tools for HCV infection and may also be developed for potential therapeutics.

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll